Recombinant Anti-CD45 x Anti-Myosin Bispecific Antibody (CrossMab) (CROSSAB-122)

Recombinant Anti-CD45 x Anti-Myosin Bispecific Antibody (CrossMab) is designed to be expressed as four chains with knobs-into-holes mutations and domain crossover. After one or multi-steps purification, high-purity antibody can be obtained. This BsAb can recruit stem cells to infarcted myocardium. It is designed for the research of Myocardial infarction therapy.

Datasheet INQUIRY

Specifications

Targets

CD45 & Myosin

Type

CrossMab

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Myocardial infarction

Targets

Target 1

CD45

Gene ID

5788

UniProt ID

P08575

Alternative Names

PTPRC; CD45; Cluster of differentiation 45; protein tyrosine phosphatase, receptor type C; LCA; LY5; B220; CD45; L-CA; T200; CD45R; GP180

Target 2

Myosin

Alternative Names

Myosin; ATP-dependent motor proteins

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Anti-CD45 x Anti-Myosin Bispecific Antibody (CrossMab) (CROSSAB-122). Click the button below to contact us or submit your feedback about this product.

Recombinant Anti-CD45 x Anti-Myosin Bispecific Antibody (CrossMab) (CAT#: CROSSAB-122)

Specifications

Targets

Customer Reviews and Q&As